Medtecs International Corporation Ltd. 546
SGX · Singapore · Health Technology
SGD 0.1140-0.00 (-0.87%)
Market closed· · SGD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SGD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Foghorn and Eli Lilly decided to stop developing FHD-909 after reviewing Phase 1 clinical data.
CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with anti-PD-1 Discussion Highlights ERNA-101’s Near-Term Milestones and Broader Potential Across Difficult-to-Treat Solid Tumors Access the Ernexa CEO Corner here CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing nov
An income portfolio built inside one sector carries one set of risks. This basket spreads five dividend payers across four sectors: consumer staples with Coca-Cola (NYSE:KO) and PepsiCo (NASDAQ:PEP), financials with JPMorgan Chase (NYSE:JPM), real estate with Realty Income (NYSE:O) and healthcare with AbbVie (NYSE:ABBV). The sections run by sector because the goal is diversity […]
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.